Profile: GSK's David Leather On Transitioning from GP And Radio Doctor to Real World Evidence Tsar
Executive Summary
David Leather – the man behind GlaxoSmithKline's ground-breaking real-world evidence initiative, the Salford Lung Study – is GSK’s in-house real world evidence expert. He spoke with Scrip about his transition from the National Health Service to industry, what it was like to set up Viiv with Pfizer and the future of RWE.
You may also be interested in...
Real-World Evidence: Lessons From GSK's Salford Lung Study
The Salford Lung Study is pioneering in the emerging field of gathering real-world evidence. David Leather, Global Medical Affairs Leader in the Respiratory Franchise at GSK, led the UK-based study and talked to the Pink Sheet about why it was important for GSK and what may come next.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.